Expression-based drug screening of neural progenitor cells from individuals with schizophrenia

Unbiased large scale screening of small molecules for drug discovery in psychiatric disease is technically challenging and financially costly. Here, Readhead and colleagues integrate in silico and in vitro approaches to design and conduct transcriptomic drug screening in schizophrenia patient-derive...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Benjamin Readhead, Brigham J. Hartley, Brian J. Eastwood, David A. Collier, David Evans, Richard Farias, Ching He, Gabriel Hoffman, Pamela Sklar, Joel T. Dudley, Eric E. Schadt, Radoslav Savić, Kristen J. Brennand
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Q
Acceso en línea:https://doaj.org/article/ed2d9e5658de4fa6b0313e02ddefca0f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Unbiased large scale screening of small molecules for drug discovery in psychiatric disease is technically challenging and financially costly. Here, Readhead and colleagues integrate in silico and in vitro approaches to design and conduct transcriptomic drug screening in schizophrenia patient-derived neural cells, in order to survey novel pathologies and points of intervention.